This study tests a drug called efruxifermin against a placebo in 700 adults with fatty liver disease (NASH/MASH). The goal is to see if the drug is safe and can reduce liver scarring. Participants must have signs of metabolic syndrome or type 2 diabetes and a confirmed liver diag…
Phase: PHASE3 • Sponsor: Akero Therapeutics, Inc • Aim: Disease control
Last updated May 26, 2026 12:10 UTC